Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of resmetirom in noncirrhotic NASH with fibrosis
MOH_2019-08-12_007338Phase 3Active, not recruiting
- Sponsor
- Madrigal Pharmaceuticals, Inc
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of resmetirom in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (3 arms), sponsored by Madrigal Pharmaceuticals, Inc. Primary endpoint: Primary endpoints not provided in registry extract. Started Jul 2019; status: active, not recruiting.
02
Drugs
resmetirom
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2019-08-12_007338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-12_007338.